Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992836 · ClinicalTrials.gov registry record · Phase 2
Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT00992836 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 155 participants.
The verdict
NCT00992836, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
Children and people infected with HIV are particularly susceptible to influenza infections. This study testED the safety and effectiveness of a vaccine for the new H1N1 influenza virus in children and youth infected with HIV.
Interventions
- BIOLOGICAL Influenza A (H1N1) 2009 monovalent vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00992836
The ClinicalTrials.gov registry entry for NCT00992836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza A (H1N1) 2009 monovalent vaccine is the first listed.
NCT00992836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00992836 about?
NCT00992836 is a clinical study titled "Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth". Children and people infected with HIV are particularly susceptible to influenza infections. This study testED the safety and effectiveness of a vaccine for the new H1N1 influenza virus in children and youth infected with HIV.
What is the current status of trial NCT00992836?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2009-10. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00992836?
The interventions under investigation include: Influenza A (H1N1) 2009 monovalent vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00992836?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.